DK118655B - Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater. - Google Patents

Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.

Info

Publication number
DK118655B
DK118655B DK433463AA DK433463A DK118655B DK 118655 B DK118655 B DK 118655B DK 433463A A DK433463A A DK 433463AA DK 433463 A DK433463 A DK 433463A DK 118655 B DK118655 B DK 118655B
Authority
DK
Denmark
Prior art keywords
aminoalkoxyphenylalkene
derivatives
preparation
analogous process
analogous
Prior art date
Application number
DK433463AA
Other languages
Danish (da)
English (en)
Inventor
M Harper
D Richardson
A Walpole
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26260578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK118655(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB34989/62A external-priority patent/GB1013907A/en
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of DK118655B publication Critical patent/DK118655B/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/64—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
    • C07C37/66—Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK433463AA 1962-09-13 1963-09-13 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater. DK118655B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34989/62A GB1013907A (en) 1962-09-13 1962-09-13 Alkene derivatives
GB30755/65A GB1064629A (en) 1962-09-13 1965-07-20 Alkene derivatives

Publications (1)

Publication Number Publication Date
DK118655B true DK118655B (da) 1970-09-21

Family

ID=26260578

Family Applications (3)

Application Number Title Priority Date Filing Date
DK433463AA DK118655B (da) 1962-09-13 1963-09-13 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK432067AA DK117953B (da) 1962-09-13 1967-08-25 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK355571AA DK127777B (da) 1962-09-13 1971-07-19 p-(Aminoalkoksy)fenyl-stilbenderivater til anvendelse som svangerskabsforebyggende midler.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK432067AA DK117953B (da) 1962-09-13 1967-08-25 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK355571AA DK127777B (da) 1962-09-13 1971-07-19 p-(Aminoalkoksy)fenyl-stilbenderivater til anvendelse som svangerskabsforebyggende midler.

Country Status (8)

Country Link
US (1) US4536516A (sv)
BE (2) BE678807A (sv)
BR (2) BR6352734D0 (sv)
CH (3) CH441286A (sv)
DE (1) DE1568834A1 (sv)
DK (3) DK118655B (sv)
FR (1) FR1502607A (sv)
GB (1) GB1064629A (sv)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (sv) * 1962-09-13
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
HU178253B (en) * 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3462398D1 (en) * 1983-05-24 1987-04-02 Bristol Myers Co Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4806685A (en) * 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5354861A (en) * 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
ZA944377B (en) * 1993-06-24 1995-12-20 Lilly Co Eli Hypoglycemic agents
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5451590A (en) * 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
GB9326255D0 (en) * 1993-12-23 1994-02-23 Roussel Lab Ltd Medical device for the prevention and treatment of cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
ZA956029B (en) 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
EP0833624B1 (en) 1995-06-07 2007-11-07 Poniard Pharmaceuticals, Inc. Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
CA2243330A1 (en) 1996-01-20 1997-07-24 Ioana Popa Tamoxifen and analogues thereof
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6083990A (en) 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
CA2280181A1 (en) * 1997-02-09 1998-08-13 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
AU746875B2 (en) * 1997-02-27 2002-05-02 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
GB9715479D0 (en) * 1997-07-23 1997-10-01 Univ Bradford Tamoxifen and analogues thereof
JP2001515038A (ja) 1997-08-15 2001-09-18 デューク・ユニバーシティー エストロゲン依存性疾患および障害の予防または治療方法
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
NZ538498A (en) * 2002-07-30 2009-02-28 Childrens Medical Center Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
EP1667692A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005084699A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 ｈｍｇ ｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
NZ587586A (en) 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2480207C2 (ru) 2006-05-22 2013-04-27 Хормос Медикал Лтд. Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
US9693953B2 (en) 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5498168B2 (ja) 2006-12-01 2014-05-21 ブリストル−マイヤーズ スクイブ カンパニー アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
EP3251694A1 (en) 2007-08-03 2017-12-06 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP5558358B2 (ja) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド メタボリック症候群用のｔｒａｎｓ−クロミフェン
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
AU2013215251A1 (en) 2012-01-31 2014-08-14 Novartis Ag Combination of a RTK inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP3296300B1 (en) 2012-03-05 2019-08-07 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CN103992234B (zh) * 2014-06-11 2016-05-18 扬子江药业集团江苏海慈生物药业有限公司 一种枸橼酸他莫昔芬e异构体的制备方法
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
EP3400009A2 (en) 2016-01-05 2018-11-14 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
WO2018027175A1 (en) 2016-08-04 2018-02-08 University Of Iowa Research Foundation Use of swell1 inhibitors and modulators to treat type 2 diabetes and obesity
US11040019B2 (en) 2016-08-19 2021-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
KR20200138714A (ko) 2018-02-21 2020-12-10 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 및 글루타메이트성 작용제를 사용한 병용 요법
EP3982944A4 (en) * 2019-06-10 2023-09-13 University of Iowa Research Foundation SWELL1 MODULATORS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER STEATOSIS, IMMUNE DEFICIENCIES, MALE STERILITY AND VASCULAR DISEASES
CN114133334B (zh) * 2021-11-09 2024-07-19 北京京丰制药(山东)有限公司 枸橼酸他莫昔芬的工业化制备工艺
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
BE637389A (sv) * 1962-09-13
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity

Also Published As

Publication number Publication date
DE1468088A1 (de) 1969-07-31
DK127777B (da) 1974-01-07
BE637389A (sv)
CH538447A (de) 1973-06-30
BR6678265D0 (pt) 1973-09-18
DK117953B (da) 1970-06-22
BE678807A (sv) 1966-09-30
CH441286A (de) 1967-08-15
BR6352734D0 (pt) 1973-09-18
FR1502607A (fr) 1967-11-24
US4536516A (en) 1985-08-20
DE1568834A1 (de) 1970-11-26
GB1064629A (en) 1967-04-05
CH446289A (de) 1967-11-15

Similar Documents

Publication Publication Date Title
DK117953B (da) Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK115403B (da) Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.
DK120490B (da) Fremgangsmåde til fremstilling af thiaxanthenderivater.
DK104675C (da) Fremgangsmåde til fremstilling af 3-hydroxy-N-nitro-picolinamid.
DK115325B (da) Fremgangsmåde til fremstilling af fenylalkylsulfamider.
DK103476C (da) Fremgangsmåde til fremstilling af 2-oxa-3-oxo-steroider.
DK108915C (da) Fremgangsmåde til fremstilling af 21-acyloxy-acetyloxy-corticosteroider.
DK103512C (da) Fremgangsmåde til fremstilling af 3-nitroso-2-oxazolidon.
DK102920C (da) Fremgangsmåde til fremstilling af 1-cyancolchicinderivater.
DK105161C (da) Fremgangsmåde til fremstilling af 3α-phenylgranatanderivater.
DK104680C (da) Fremgangsmåde til fremstilling af derivater af 6-methyl-8-aminomethyl-ergolin I.
DK104063C (da) Fremgangsmåde til fremstilling af 4-hydroxy-5-halogenpyrimidiner.
DK113647B (da) Fremgangsmåde til fremstilling af 2-sulfanilamido-5-metoxypyrimidin.
DK115620B (da) Fremgangsmåde til fremstilling af 17α-klorætynyl-17βalkoksysteroider.
DK104065C (da) Fremgangsmåde til fremstilling af 3-phenylgranaten-(2)-derivater.
DK122391B (da) Analogifremgangsmåde til fremstilling af 2-hydroxybenzopyridocolinderivater.
DK105766C (da) Fremgangsmåde til fremstilling af 1-hydroxymethyldesacetylaminothiocolchicinderivater.
DK105532C (da) Fremgangsmåde til fremstilling af 1-hydroxymethyl-14-aminocolchicinderivater.
DK104941C (da) Fremgangsmåde til fremstilling af 1-hydroxymethylthiocolchicinderivater.
DK104413C (da) Fremgangsmåde til fremstilling af 1-hydroxymethylcolchicinderivater.
DK104105C (da) Fremgangsmåde til fremstilling af 2-alkoxycycloheptimidazol-derivater.
DK102746C (da) Fremgangsmåde til fremstilling af 3β-fenylgranatanderivater.
DK115555B (da) Fremgangsmåde til fremstilling af nitrofurfurylidenderivater.
DK103505C (da) Fremgangsmåde til fremstilling af 4-N-demethyl-4-N-ethyl-oxytetracyclin.
DK103833C (da) Fremgangsmåde til fremstilling af desacetylamino-N-methylcolchiceinamid.